8-K: AngioDynamics Reports Strong Q3 2025 Results, Raises Full-Year Guidance

AngioDynamics announces positive Q3 2025 financial results with significant growth in MedTech sales and increased full-year guidance across key metrics.

Summary

• AngioDynamics reported a 9.2% increase in pro forma net sales for Q3 2025, reaching $72.0 million.
• MedTech net sales grew by 22.2% to $31.3 million, driven by strong performance across Auryon, AngioVac, AlphaVac, and NanoKnife product lines.
• Med Device net sales saw a slight increase of 0.9% to $40.7 million.
• The company's GAAP gross margin improved to 54.0%, up 290 basis points year-over-year.
• AngioDynamics reported a GAAP loss per share of $(0.11) and an adjusted loss per share of $(0.08).
• Adjusted EBITDA was $1.3 million, a significant improvement from a loss of $3.6 million in the same quarter last year.
• The company initiated the AMBITION BTK RCT and Registry to support the use of the Auryon Atherectomy System.
• The APEX-AV trial results, demonstrating the safety and efficacy of the AlphaVac F1885 System, were published in JSCAI.
• The NanoKnife System received FDA 510(k) clearance for prostate tissue ablation.
• AngioDynamics is increasing its fiscal year 2025 guidance for net sales, MedTech net sales growth, gross margin, Adjusted EBITDA, and Adjusted EPS.
• The company expects to generate positive operating cash flow in the fourth quarter of fiscal 2025 and for the full year of fiscal 2026.
• Subsequent to the end of the third quarter, AngioDynamics secured a $25.0 million revolving line of credit agreement with J.P. Morgan.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong growth in key segments, improved profitability, and increased guidance. The FDA clearance and clinical trial progress further contribute to the positive sentiment.

Positives

• Strong growth in MedTech segment, driven by key product lines.
• Improved gross margins and operational efficiency.
• Positive adjusted EBITDA, indicating improved profitability.
• FDA clearance for NanoKnife System for prostate tissue ablation.
• Increased full-year guidance for key financial metrics.
• Initiation of clinical trials to support product adoption.
• Publication of positive clinical trial results for AlphaVac.
• Secured a $25.0 million revolving line of credit, providing financial flexibility.

Negatives

• The company recorded a GAAP net loss of $4.4 million, or a loss per share of $0.11.
• The company utilized $13.2 million in operating cash in the third quarter of fiscal 2025.
• Med Device net sales only increased 0.9%.

Risks

• The document contains forward-looking statements that are subject to various risks and uncertainties.
• These risks include the ability to develop new products, competition, regulatory actions, economic conditions, and litigation.
• The company's actual results may differ materially from its expectations.

Future Outlook

AngioDynamics has increased its full-year 2025 guidance for net sales to $285-$288 million, MedTech net sales growth to 14-16%, gross margin to 53-54%, adjusted EBITDA to $4.0-$5.0 million, and adjusted loss per share to $(0.31)-$(0.34).

Management Comments

• Jim Clemmer, President and Chief Executive Officer of AngioDynamics, stated that the company is very pleased with its third quarter performance.
• Mr. Clemmer highlighted the strong topline growth and adjusted EBITDA profitability.
• Mr. Clemmer noted the impressive momentum across the MedTech franchise, which grew over 20% for the second quarter in a row.
• Mr. Clemmer stated that the company is well positioned to deliver profitable growth going forward.
• Mr. Clemmer mentioned that the portfolio is the strongest it has been, with improved operating leverage and a strong balance sheet.

Industry Context

AngioDynamics operates in the medical technology industry, focusing on restoring healthy blood flow, expanding cancer treatment options, and improving patient quality of life; the company's performance reflects the demand for innovative medical devices and therapies in these areas.

Comparison to Industry Standards

• The company's MedTech growth of 22.2% significantly outpaces the overall medical device industry growth.
• The company's focus on minimally invasive procedures aligns with industry trends towards less invasive treatments.
• The company's investment in clinical trials and regulatory approvals demonstrates a commitment to evidence-based medicine, which is a key factor for success in the medical device industry.
• Companies like Medtronic, Boston Scientific, and Abbott are major players in the medical device industry, and AngioDynamics competes with them in certain segments.
• The company's focus on specific niches, such as thrombus management and irreversible electroporation, allows it to differentiate itself from larger competitors.

Stakeholder Impact

• Shareholders: Positive results and increased guidance are likely to be viewed favorably by shareholders.
• Employees: Strong performance and growth prospects may improve employee morale and job security.
• Customers: FDA clearance and clinical trial progress may increase confidence in the company's products.
• Suppliers: Increased sales and production may lead to higher demand for raw materials and components.
• Creditors: Improved profitability and a new line of credit may enhance the company's creditworthiness.

Next Steps

• Continue commercial execution to drive revenue growth.
• Advance clinical trials and registries to generate clinical evidence.
• Expand commercial launch of NanoKnife for prostate tissue ablation.
• Launch new products to refine and enhance usability of existing products.
• Increase penetration in the hospital setting for Auryon.
• Execute full commercial launch of PE indication for AlphaVac in the U.S. and CE Marked countries.

Key Dates

Keywords

AngioDynamics, financial results, MedTech, Med Device, NanoKnife, AlphaVac, Auryon, AngioVac, EBITDA, guidance, FDA clearance, clinical trial